A Trial of a Modified Cystoscopy Method to Reduce Pain Perception
A Randomized Control Trial of a Modified Cystoscopy Method to Reduce Pain Perception
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada
- London Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients over the age of 18 undergoing cystoscopy for the first time for diagnostic investigation will be approached to participate in this study.
Exclusion Criteria:
- Cystoscopies involving other interventions concurrently (e.g. biopsy, urethral dilation, removal of ureteral stent, etc.) will be excluded.
- Patients currently taking medication for chronic pain (e.g. opioids, Tricyclic antidepressants (TCAs)) will be excluded from the study.
- Patients less than 18 years of age will be excluded.
- Patients who have received a cystoscopy previously will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Routine Cystoscopy
|
Routine cystoscopy as done as part of routine clinical practice
|
|
Experimental: Modified Cystoscopy
|
The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Experience rated on the visual analogue scale
Time Frame: 1 hour
|
The primary outcome of the study will be pain experience, as rated on the visual analogue scale provided.
|
1 hour
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nicholas Power, MD, London Health Sciences Centre
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 10016740
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
NCT02735512TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder Cancer
-
NCT04598724CompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IV
-
NCT01611662TerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder Cancer
-
NCT02252393WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
NCT00666562CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
NCT00072137TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder Cancer
-
NCT03844256Recruiting
-
NCT00003167CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder Cancer
-
NCT01938573CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder Cancer
-
NCT03498196TerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder Cancer
Clinical Trials on Routine Cystoscopy
-
NCT01912339CompletedBenign Prostatic Hyperplasia | Lower Urinary Tract Symptom
-
NCT01971437CompletedUrinary Incontinence, Urge
-
NCT03790826UnknownBladder Infections and Inflammations
-
NCT07618221Not yet recruitingHematuria | Bladder Disease | Hematuria - Cause Not Known | Macrohematuria
-
NCT03148158UnknownPain, Postoperative | Bladder Cancer | Flexible Cystoscopy | Non-muscle Invasive Bladder Cancer (NMIBC)
-
NCT00214045CompletedUrination Disorders | Hematuria | Recurrent Urinary Tract Infection | Voiding Dysfunction
-
NCT00177112CompletedUrinary Tract Infections